A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC)

By Raez Luis   Santos Edgardo   Webb R.   Wade James   Brito Roger   Karr Melissa   Kennah Andra   Childs Barrett  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 1103-1110

Springer Publishing Company

Access to resources Recommend Favorite

Targeted therapy for non-small-cell lung cancer: past, present and future

By Forde Patrick M   Ettinger David S  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 745-758

Informa Healthcare

Access to resources Recommend Favorite

Evolution of modern-era radiotherapy strategies for unresectable advanced non-small-cell lung cancer

By Selek Ugur   Chang Joe Y  

Lung Cancer Management, Vol. 2, Iss. 3, 2013-06 ,pp. : 213-225

Future Medicine

Access to resources Recommend Favorite

Afatinib in advanced non-small-cell lung cancer

By Di Maio Massimo   Gridelli Cesare   Grossi Francesco   Novello Silvia   de Marinis Filippo  

Lung Cancer Management, Vol. 2, Iss. 6, 2013-12 ,pp. : 493-504

Future Medicine

Access to resources Recommend Favorite

Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in unresectable and locally advanced non-small cell lung cancer

By Oka M.   Fukuda M.   Fukuda M.   Kinoshita A.   Kuba M.   Ichiki M.   Rikimaru T.   Soda H.   Takatani H.   Narasaki F.   Nagashima S.   Nakamura Y.-I.   Hayashi N.   Kohno S.  

European Journal of Cancer, Vol. 37, Iss. 11, 2001-07 ,pp. : 1359-1365

Elsevier

Access to resources Recommend Favorite